316 related articles for article (PubMed ID: 34806449)
1. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
2. Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease.
Trant J; Sanchez G; McDermott JP; Blanco G
Am J Physiol Renal Physiol; 2023 Dec; 325(6):F857-F869. PubMed ID: 37823195
[TBL] [Abstract][Full Text] [Related]
3. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.
Hopp K; Kleczko EK; Gitomer BY; Chonchol M; Klawitter J; Christians U; Klawitter J
Am J Physiol Renal Physiol; 2022 Mar; 322(3):F258-F267. PubMed ID: 35037466
[TBL] [Abstract][Full Text] [Related]
4. Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice.
Chang MY; Tsai CY; Chou LF; Hsu SH; Yang HY; Hung CC; Tian YC; Ong ACM; Yang CW
Hum Mol Genet; 2022 May; 31(10):1560-1573. PubMed ID: 34957500
[TBL] [Abstract][Full Text] [Related]
5. Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.
Leonhard WN; Song X; Kanhai AA; Iliuta IA; Bozovic A; Steinberg GR; Peters DJM; Pei Y
EBioMedicine; 2019 Sep; 47():436-445. PubMed ID: 31473186
[TBL] [Abstract][Full Text] [Related]
6. Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD.
Leuenroth SJ; Bencivenga N; Chahboune H; Hyder F; Crews CM
Nephrol Dial Transplant; 2010 Jul; 25(7):2187-94. PubMed ID: 20139063
[TBL] [Abstract][Full Text] [Related]
7. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
10. Renal cyst growth is the main determinant for hypertension and concentrating deficit in Pkd1-deficient mice.
Fonseca JM; Bastos AP; Amaral AG; Sousa MF; Souza LE; Malheiros DM; Piontek K; Irigoyen MC; Watnick TJ; Onuchic LF
Kidney Int; 2014 May; 85(5):1137-50. PubMed ID: 24429399
[TBL] [Abstract][Full Text] [Related]
11. Cux1 promotes cell proliferation and polycystic kidney disease progression in an ADPKD mouse model.
Porath B; Livingston S; Andres EL; Petrie AM; Wright JC; Woo AE; Carlton CG; Baybutt R; Vanden Heuvel GB
Am J Physiol Renal Physiol; 2017 Oct; 313(4):F1050-F1059. PubMed ID: 28701314
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease.
Zhang C; Balbo B; Ma M; Zhao J; Tian X; Kluger Y; Somlo S
J Am Soc Nephrol; 2021 Jan; 32(1):41-51. PubMed ID: 33046531
[TBL] [Abstract][Full Text] [Related]
13. Effect of celastrol on the progression of polycystic kidney disease in a Pkd1-deficient mouse model.
Chang MY; Hsieh CY; Lin CY; Chen TD; Yang HY; Chen KH; Hsu HH; Tian YC; Chen YC; Hung CC; Yang CW
Life Sci; 2018 Nov; 212():70-79. PubMed ID: 30268856
[TBL] [Abstract][Full Text] [Related]
14. VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation.
Yanda MK; Cebotaru L
FASEB J; 2021 Nov; 35(11):e21987. PubMed ID: 34662459
[TBL] [Abstract][Full Text] [Related]
15. CD8
Kleczko EK; Marsh KH; Tyler LC; Furgeson SB; Bullock BL; Altmann CJ; Miyazaki M; Gitomer BY; Harris PC; Weiser-Evans MCM; Chonchol MB; Clambey ET; Nemenoff RA; Hopp K
Kidney Int; 2018 Dec; 94(6):1127-1140. PubMed ID: 30249452
[TBL] [Abstract][Full Text] [Related]
16. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.
Seeger-Nukpezah T; Proia DA; Egleston BL; Nikonova AS; Kent T; Cai KQ; Hensley HH; Ying W; Chimmanamada D; Serebriiskii IG; Golemis EA
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12786-91. PubMed ID: 23858461
[TBL] [Abstract][Full Text] [Related]
18. The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.
Ye H; Wang X; Constans MM; Sussman CR; Chebib FT; Irazabal MV; Young WF; Harris PC; Kirschner LS; Torres VE
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F677-F686. PubMed ID: 28615245
[TBL] [Abstract][Full Text] [Related]
19. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1
Arroyo J; Escobar-Zarate D; Wells HH; Constans MM; Thao K; Smith JM; Sieben CJ; Martell MR; Kline TL; Irazabal MV; Torres VE; Hopp K; Harris PC
Kidney Int; 2021 Jun; 99(6):1392-1407. PubMed ID: 33705824
[TBL] [Abstract][Full Text] [Related]
20. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.
Sundar SV; Zhou JX; Magenheimer BS; Reif GA; Wallace DP; Georg GI; Jakkaraj SR; Tash JS; Yu ASL; Li X; Calvet JP
Am J Physiol Renal Physiol; 2022 Oct; 323(4):F492-F506. PubMed ID: 35979967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
